TCR-Based Antibodies, Fusion Proteins and Cell-Penetrating Biologics to Tap the Intracellular Target Pool
- Category: Antibodies
- Published on Friday, 02 March 2018 11:49
- Hits: 772
- New report about T-Cell Receptor-based Biologics
- Spring promotion: 10% discount until March 15, 2018
STUTTGART, Germany I March 2, 2018 I In a new report released by La Merie Publishing the competitive landscape of target and TCR disovery technologies and of the new therapeutic modalities TCR fusion proteins, TCR-like antibodies and cell-penetrating biologics is described and analyzed.
A tissue-based map of the human proteome suggests that about 75 % are intracellular or secreted targets not accessible for conventional monoclonal antibody and chimeric antigen receptor (CAR) T-cell therapy (Uhlen et al., Science, 2015). Thus, the large pool of intracellular protein targets, including overexpressed oncogenic proteins, mutated tumor suppressors and gene products of translocation, remains untapped so far. Part of the intracellular antigen proteins are degraded to protein fragments that are eventually presented on the cell surface as a composite antigen comprised of a variable linear sequence peptide (typically 9-10 amino acids in length) buried within a major histocompatibility complex (MHC) molecule, also referred to as human leukocyte antigen (HLA) class I, for recognition by T-cell receptors.
Emerging technologies addressing intracellular targets presented as p/MHC epitopes on the cell surface include TCR-engineered T-cells and recombinant TCR fusion proteins, in addition to TCR-like (TCRL) or TCR mimic antibodies. Cell-penetrating biologics are directly addressing targets located within the cell, or even in the nucleus, especially protein-protein interactions.
The report „Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends“ brings you up-to-date regarding emerging key technologies
- for identification and validation of intracellular targets,
- for generation of T-cell receptors (TCR) and TCR fusion proteins,
- for discovery of TCR-like antibodies, and
- for construction of cell-penetrating peptides, proteins and antibodies.
The report furthermore describes the profiles of leading product candidates created by these technologies. The technology companies are presented and analyzed. Deals between Big Pharma and technology companies as well as collaboration and licensing deals between technology companies are highlighted. The value of technologies and product candidates are discussed regarding company acquisition prices, economic deal terms and financing rounds.
About La Merie
La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports. For more information visit www.lamerie.com and www.PipelineReview.com, the Biologics News Center and Online Store of La Merie Publishing.
SOURCE: La Merie Publishing